CD8A and Miyoshi myopathy: The antibody has been approved by FDA for MM treatment. It is also used to resist the toxicity of CD38+CD8+ T cells in AD patients. However, no improvement of cognition has been found with daratumumab treatment according to the result of phase II trial (NCT04070378).